Mandate

Vinge advises Capio in connection with the acquisition of the Nova clinics

February 26, 2018 M&A

Vinge has advised Capio, which is listed on Nasdaq Stockholm, in connection with the acquisition of the shares in the Nova clinics.

The Nova clinics primarily conduct healthcare operations at eight clinics in the southeast of Skåne and have certain operations within occupational health service and dental service. In 2017, the Nova clinics had a turnover of approximately MSEK 245 and had approximately 45 000 listed patients. The purchase price mechanism, which is based on Enterprise Value, amounts to MSEK 88. The acquisition is conditional upon the Swedish Competition Authority’s and Region Skåne’s approval.

Vinge’s team consisted of Anders Strid, Frida Bäckegren (project manager), Gabriella Fossum (LOU), Rebecka Maltenius (commercial property law), Lina André (employment law), Camilla Andersson (company registration assistant) as well as Pär Remenlid and Nils Alvång (both competition law).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024